Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Oral Nirmatrelvir and Ritonavir in Nonhospitalized Vaccinated Patients With Coronavirus Disease 2019
Sarju Ganatra, Sourbha S. Dani, Javaria Ahmad, et al.
Clinical Infectious Diseases (2022) Vol. 76, Iss. 4, pp. 563-572
Open Access | Times Cited: 130

Showing 1-25 of 130 citing articles:

Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System
Scott Dryden‐Peterson, Andy Kim, Arthur Y. Kim, et al.
Annals of Internal Medicine (2022) Vol. 176, Iss. 1, pp. 77-84
Open Access | Times Cited: 140
Real-world use of nirmatrelvir–ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study
Neil Krishan Aggarwal, Kyle C. Molina, Laurel Beaty, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 6, pp. 696-705
Open Access | Times Cited: 98
Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?
Seyed Mohammad Reza Hashemian, Amirhossein Sheida, Mohammad Taghizadieh, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 162, pp. 114367-114367
Open Access | Times Cited: 90
Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID‐19: A rapid review and meta‐analysis
Behnam Amani, Bahman Amani
Journal of Medical Virology (2022) Vol. 95, Iss. 2
Open Access | Times Cited: 87
Paxlovid Associated with Decreased Hospitalization Rate Among Adults with COVID-19 — United States, April–September 2022
Melisa M. Shah, Brendan Joyce, Ian D. Plumb, et al.
MMWR Morbidity and Mortality Weekly Report (2022) Vol. 71, Iss. 48, pp. 1531-1537
Open Access | Times Cited: 84
Population-based evaluation of the effectiveness of nirmatrelvir–ritonavir for reducing hospital admissions and mortality from COVID-19
Kevin L. Schwartz, Jun Wang, Mina Tadrous, et al.
Canadian Medical Association Journal (2023) Vol. 195, Iss. 6, pp. E220-E226
Open Access | Times Cited: 78
Efficacy and safety of Paxlovid for COVID-19:a meta-analysis
Qian Zheng, Pengfei Ma, Mingwei Wang, et al.
Journal of Infection (2022) Vol. 86, Iss. 1, pp. 66-117
Open Access | Times Cited: 73
SARS-CoV-2 Virologic Rebound With Nirmatrelvir–Ritonavir Therapy
Gregory E. Edelstein, Julie Boucau, Rockib Uddin, et al.
Annals of Internal Medicine (2023) Vol. 176, Iss. 12, pp. 1577-1585
Open Access | Times Cited: 44
Nirmatrelvir–ritonavir for the treatment of COVID‐19 patients: A systematic review and meta‐analysis
Huzaifa Ahmad Cheema, Uzair Jafar, Aruba Sohail, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 2
Closed Access | Times Cited: 41
Oral Antiviral Treatment for COVID-19: A Comprehensive Review on Nirmatrelvir/Ritonavir
Karolina Akinosoglou, Georgios Schinas, Charalambos Gogos
Viruses (2022) Vol. 14, Iss. 11, pp. 2540-2540
Open Access | Times Cited: 53
Cardiovascular Drug Interactions With Nirmatrelvir/Ritonavir in Patients With COVID-19
Sonu Abraham, Anju Nohria, Tomas G. Neilan, et al.
Journal of the American College of Cardiology (2022) Vol. 80, Iss. 20, pp. 1912-1924
Open Access | Times Cited: 37
The Coronavirus Disease 2019 Rebound Study: A Prospective Cohort Study to Evaluate Viral and Symptom Rebound Differences in Participants Treated With Nirmatrelvir Plus Ritonavir Versus Untreated Controls
Jay Pandit, Jennifer M. Radin, Danielle Chiang, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 1, pp. 25-31
Open Access | Times Cited: 37
Paxlovid associated with decreased hospitalization rate among adults with COVID-19 — United States, April–September 2022
Melisa M. Shah, Brendan Joyce, Ian D. Plumb, et al.
American Journal of Transplantation (2023) Vol. 23, Iss. 1, pp. 150-155
Open Access | Times Cited: 31
Drug treatment of COVID-19 infection
Grace Lui, Giovanni Guaraldi
Current Opinion in Pulmonary Medicine (2023) Vol. 29, Iss. 3, pp. 174-183
Open Access | Times Cited: 30
Safety and Efficacy of Paxlovid Against Omicron Variants of Coronavirus Disease 2019 in Elderly Patients
Cheng‐Zhao Weng, Rongcheng Xie, Guanjie Han, et al.
Infectious Diseases and Therapy (2023) Vol. 12, Iss. 2, pp. 649-662
Open Access | Times Cited: 28
Treatments for COVID-19
Hayden S. Andrews, Jonathan D. Herman, Rajesh T. Gandhi
Annual Review of Medicine (2023) Vol. 75, Iss. 1, pp. 145-157
Closed Access | Times Cited: 25
The effect of nirmatrelvir plus ritonavir on the long-term risk of epilepsy and seizure following COVID-19: A retrospective cohort study including 91,528 patients
Ting-Hui Liu, Jheng‐Yan Wu, Po‐Yu Huang, et al.
Journal of Infection (2023) Vol. 86, Iss. 3, pp. 256-308
Open Access | Times Cited: 24
Trends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective, descriptive cohort study of 23.4 million people in OpenSAFELY
Amelia Green, Helen J Curtis, Rose Higgins, et al.
BMJ Medicine (2023) Vol. 2, Iss. 1, pp. e000276-e000276
Open Access | Times Cited: 21
Efficacy of nirmatrelvir and ritonavir for post‐acute COVID‐19 sequelae beyond 3 months of SARS‐CoV‐2 infection
Min‐Hsiang Chuang, Jheng‐Yan Wu, Tinghui Liu, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 4
Closed Access | Times Cited: 21
Oral Nirmatrelvir and Ritonavir for Coronavirus Disease 2019 in Vaccinated, Nonhospitalized Adults Aged 18–50 Years
Jeremy Samuel Faust, Ashish Kumar, Jui Shah, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 9, pp. 1257-1264
Closed Access | Times Cited: 18
Efficacy and safety of paxlovid (nirmatrelvir/ritonavir) in the treatment of COVID‐19: An updated meta‐analysis and trial sequential analysis
Haokun Tian, Changsen Yang, Tiangang Song, et al.
Reviews in Medical Virology (2023) Vol. 33, Iss. 5
Closed Access | Times Cited: 17
Real-World Effectiveness of Nirmatrelvir/Ritonavir on Coronavirus Disease 2019–Associated Hospitalization Prevention: A Population-based Cohort Study in the Province of Quebec, Canada
Jean‐Luc Kaboré, Benoît Laffont, Mamadou Diop, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 6, pp. 805-815
Open Access | Times Cited: 16
Azvudine versus paxlovid for oral treatment of COVID-19 in Chinese patients
Peng Su, Congxian Yang, Xingguang Wang
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 5
Exploring Paxlovid Efficacy in COVID-19 Patients with MAFLD: Insights from a Single-Center Prospective Cohort Study
Mykhailo Buchynskyi, Valentyn Oksenych, Iryna Kamyshna, et al.
Viruses (2024) Vol. 16, Iss. 1, pp. 112-112
Open Access | Times Cited: 5
Cost-effectiveness of nirmatrelvir/ritonavir for high-risk adult outpatients with COVID-19 in Japan
Takahito Mizuno, Yu Kondo, Mikiyasu Sakai, et al.
Journal of Infection and Chemotherapy (2024) Vol. 30, Iss. 8, pp. 716-724
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top